Triple Inhaled Therapy Reduces Cardiopulmonary Risk in COPD Patients

Learn about the promising results of triple inhaled therapy with budesonide/glycopyrrolate/formoterol fumarate in reducing the risk of cardiopulmonary events in individuals with COPD. The post-hoc analysis based on the ETHOS phase 3 clinical trial showed a 20% reduction in risk compared to dual therapy, offering hope for improved outcomes and enhanced quality of life for COPD patients.